Analogs of M4 selective synthetic muscarinic receptor antagonists:: Synthesis, binding and pharmacokinetic properties

被引:0
|
作者
Böhme, TM
Augelli-Szafran, CE
Hallak, H
Schwarz, RD
机构
[1] Pfizer Global Res & Dev, Dept Med, Ann Arbor, MI 48105 USA
[2] Pfizer Global Res & Dev, Dept Chem, Ann Arbor, MI 48105 USA
[3] Pfizer Global Res & Dev, CNS Pharmacol, Ann Arbor, MI 48105 USA
关键词
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Recently, highly selective M-4 muscarinic receptor antagonists (e.g., PD 0320115) have been synthesized and pharmacologically characterized. One compound, PD 0298029 which was selected for in vivo testing, had low bioavailability (rat similar to5 %) and proved to be susceptible to fast metabolism resulting in high clearance (rat: 60 mL / min / kg). In an effort to improve stability, we focused on the replacement of the hemi-aminal structure in PD 0298029, a moiety which may cause this instability. Therefore, the oxygen of the hemi-aminal was exchanged with a carbon. The in vivo pharmacokinetic data clearly indicated that this change yielded a more stable compound (rat: clearance: 8 mL / min / kg) with improved bioavailability (similar to30 %). However, this substitution significantly decreased the binding affinity at M-4 receptors. Another potential unstable moiety in the molecule is the ester group in PD 0298029 that may undergo enzymatic cleavage. Replacing this ester group with an oxadiazole moiety was synthesized. While M-4 affinity was reduced, bioavailability was increased higher (rat: similar to44 %) but high clearance (rat: 78 mL / min / kg) was retained.
引用
收藏
页码:423 / 433
页数:11
相关论文
共 50 条
  • [41] The muscarinic M4 acetylcholine receptor exacerbates symptoms of movement disorders
    Chambers, Nicole E.
    Millett, Michael
    Moehle, Mark S.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2023, 51 (02) : 691 - 702
  • [42] Muscarinic M4 receptor changes in the hippocampus and entorhinal cortex of adrenalectomized
    Mulugeta, E
    Fahim, MA
    Hasan, MY
    El-Bakri, N
    Winblad, B
    Karlsson, E
    Adem, A
    FASEB JOURNAL, 2004, 18 (05): : A1256 - A1256
  • [43] Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia
    Pozhidaev, Ivan, V
    Boiko, Anastasiia S.
    Loonen, Anton J. M.
    Paderina, Diana Z.
    Fedorenko, Olga Yu
    Tenin, Gennadiy
    Kornetova, Elena G.
    Semke, Arkadiy, V
    Bokhan, Nikolay A.
    Wilffert, Bob
    Ivanova, Svetlana A.
    APPLICATION OF CLINICAL GENETICS, 2020, 13 : 97 - 105
  • [44] Hippocampal muscarinic M4 receptor changes in Alzheimer's disease
    Adem, A
    Mulugeta, E
    Karlsson, E
    Islam, A
    Winblad, B
    Kalaria, RN
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S524 - S524
  • [45] Muscarinic m4 receptor activation by some atypical antipsychotic drugs
    Zeng, XP
    Le, F
    Richelson, E
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 321 (03) : 349 - 354
  • [46] Muscarinic receptor subtype M4 in signal transduction and memory consolidation
    Sanchez, Gonzalo
    Blanco, Carlos
    Colletis, Natalia
    Quillfeldt, Jorge
    Jerusalinsky, Diana
    Kornisiuk, Edgar
    PSYCHOPHYSIOLOGY, 2006, 43 : S85 - S85
  • [47] Structure of the m4 cholinergic muscarinic receptor gene and its promoter
    Wood, IC
    Roopra, A
    Harrington, C
    Buckley, NJ
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (52) : 30933 - 30940
  • [48] THE BINDING-PROPERTIES OF SELECTIVE MUSCARINIC ANTAGONISTS IN RAT-BRAIN
    EHLERT, FJ
    TRAN, P
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (05) : 1720 - 1721
  • [49] Development of muscarinic m3 and m4 receptor antibodies with pharmacological activities
    王海鹰
    曾淑君
    邱鹏新
    Acta Pharmacologica Sinica, 1998, (06) : 24 - 27
  • [50] Altered distribution of M2 and M4 muscarinic receptor expression in vitiligo
    Chaichalotornkul, Sirintip
    Udompataikul, Montree
    Showpittapornchai, Udomsri
    Palungwachira, Piti
    Pradidarcheep, Wisuit
    JOURNAL OF DERMATOLOGY, 2011, 38 (05): : 493 - 497